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A B S T R A C T
The incorporation of poly(DL-lactic-co-glycolic acid) (PLGA) particles into calcium phosphate cements (CPCs) is
an effective strategy to enhance CPC macroporosity and degradation. However, bone regeneration is hindered
until hydrolytic PLGA degradation starts a few weeks after implantation. Additionally, CPC and CPC/PLGA
injectability and cohesion are suboptimal. In the current study, poly(N-vinylpyrrolidone) (PVP), a water-soluble
polymer, was incorporated as a porogen in CPC and CPC/PLGA composites to enhance handling properties and
early-stage macroporosity formation. Further, the effect of PVP molecular weight (Mw) and particle size was
studied. The results showed that PVP incorporation increased both injectability and cohesion of the CPC pastes,
especially with addition of high Mw PVP. Moreover, the in vitro degradation studies revealed that incorporation
of PVP induced an initial mass loss during the first week of incubation. In combination with PLGA, small PVP
particles induced a higher mass loss at an early stage than large PVP particles, but this effect was no longer
apparent after 4 weeks of incubation. In contrast, the incorporation of low Mw PVP had a stronger effect on in
vitro degradation in the long term compared to high Mw. Finally, the presence of PLGA porogens appeared to be
necessary for adequate CPC degradation.
1. Introduction
The regeneration of bone defects has been extensively studied in
maxillofacial and orthopedic surgery. Bone defects can arise from en-
dogenous (e.g. cysts, tumors, or congenital deformities) or exogenous
causes (e.g. injuries from accidents) and its regeneration may require
the use of bone regeneration techniques [1]. The gold standard in bone
regeneration techniques is the use of bone grafts and, specifically, the
use of autografts. However, autografts have different drawbacks, such
as low availability or secondary surgery site and donor site morbidity,
among others [2]. Synthetic bone grafts, such as polymers or ceramics,
are a promising alternative as they are off-the-shelf available. On the
other hand, one of the current demands in reconstructive surgery is the
degradability of bone substitutes [3,4]. Bone substitutes are destined to
dissolve and degrade postoperatively synchronized with bone healing
periods, so that they do not hinder new bone formation. Therefore, the
design and construction of degradable bone substitutes is of high im-
portance.
Calcium phosphate (CaP)-based materials are one of the most used
synthetic bone substitutes. Of those, calcium phosphate cements (CPCs)
seem the most appealing, due to their injectable and moldable nature.
CPCs are composed of a powder and a liquid phase that, when mixed,
form a paste that sets and hardens into a solid mass. Depending on the
end product of the setting reaction, CPCs can be classified in apatitic
and brushite cements. While brushite cements have a higher degrada-
tion rate than apatitic CPCs, the latter have a more similar mineral
phase to bone and superior mechanical properties [5–7]. The downside
of apatitic CPCs is that they are slowly biodegraded and thus hamper
the replacement of the CPC with native bone tissue [8–11]. Therefore,
the degradation of apatitic CPCs has to be enhanced so that their re-
placement with native bone tissue can occur.
In order to accelerate apatitic CPC degradation, macroporosity can
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be introduced. It is known that the presence of macroporosity can en-
hance the active and passive degradation of CPCs by allowing cell mi-
gration and proliferation into the CPC matrix as well as by increasing
the surface area [12–14]. Consequently, numerous strategies have been
pursued to increase the macroporosity of apatitic CPCs. The use of
polymeric microparticles, also known as polymeric porogens, into
apatitic CPC is among the most extensively used approaches. Poly(D,L-
lactic-co-glycolic acid) (PLGA) has shown to be a great polymeric
candidate; its hydrolytic degradation not only creates a macroporous
structure within the CPC, but also produces acidic monomers (i.e. lactic
and glycolic acid) that further enhance the degradation of the CPC
matrix [15,16]. However, bone ingrowth into the CPC is delayed until
PLGA degradation starts ∼2 weeks after implantation [17].
Water-soluble porogens, on the other hand, create a nearly im-
mediate macroporous structure. Nevertheless, the addition of water-
soluble polymers to CPCs would only enhance degradability by creating
macroporosity and increasing the surface available to degrade, but it
would not affect the structure of the CPC matrix itself. Previous work
focused on the combination of a water-soluble porogen, such as sucrose
and PLGA, to obtain a multimodal porogen system with fast macro-
porosity created by the sucrose and late stage macroporosity as well as
CPC degradation enhancement due to PLGA degradation [18,19].
However, sucrose dissolution occurred too early, and, therefore, it
might fully dissolve before CPC setting is completed which can cause
matrix densification [20]. Furthermore, the incorporation of sucrose in
CPC/PLGA systems increased the final setting time to ∼80min and
reduced the CPC paste cohesion.
A solution for this problem can be the use of water-soluble poly-
mers, as their dissolution can be tuned. Poly(N-vinylpyrrolidone) (PVP)
is a water-soluble polymer that is already being used on a wide-scale for
commercial purposes in the food, cosmetic or pharmaceutical in-
dustries. Also, PVP has been used as a lubricating agent for injections,
making it an excellent material to add to CPC regarding the injectability
properties [21–23]. Moreover, PVP has been previously incorporated
into the liquid phase of CPCs to act as a cohesion enhancer [24].
Therefore, we hypothesized that the use of a dual porogen system
combining the water-soluble polymer PVP with hydrolytically de-
grading PLGA would 1) improve CPC paste injectability and cohesion,
and 2) create an early macroporous structure due to PVP dissolution
and a later stage CPC degradation due to PLGA hydrolytic degradation.
Additionally, we hypothesized that porogen size and molecular weight
(Mw) would have an effect on CPC handling properties and would af-
fect PVP dissolution. For this, handling properties were explored and in
vitro degradation experiments of CPCs including PVP particles of dif-
ferent sizes and Mw with and without PLGA were performed.
2. Materials and methods
2.1. Materials
CPC powder consisted of 100 % alpha tricalcium phosphate (α-TCP)
(CAM Bioceramics BV; Leiden, The Netherlands). The liquid phase for
the cement preparation was sodium dihydrogen phosphate dihydrate
(NaH2PO4·2 H2O) and was purchased from Merck (Darmstadt,
Germany). PLGA (lactic:glycolic acid ratio 50:50; molecular weight of
17 kDa; acid terminated) was used (Corbion Purac, Gorinchem, The
Netherlands) in the form of microparticles (mean particle size of ap-
proximately 60 μm). Poly(N-vinylpyrrolidone) (PVP) with a Mw of
10 kDa was purchased from Sigma-Aldrich (Zwijndrecht, The
Netherlands) and sieved to a particle size of> 40 μm (S-lMw, mean
particle size of ∼50 μm). PVP with a Mw of 360 kDa was purchased
from Sigma-Aldrich (Zwijndrecht, The Netherlands) and sieved to a
particle size of< 100 μm (S-hMw, mean particle size of ∼50 μm)
and>100 μm (L-hMw, mean particle size of ∼200 μm). The size dis-
tribution of all three types of PVP was determined by image analysis.
The different PVP particles were observed with an optical microscope
(Leica Microsystems AG, Wetzlar, Germany). Subsequently, size dis-
tribution was determined from 250 PVP particles of each group by di-
gital image software (Fiji 1.51n) [25].
2.2. Preparation of CPC formulations
PVP with different particle size and Mw and/or PLGA particles were
added to α-TCP in different ratios (Table 1). The different CPC for-
mulations were mixed with 4 wt/vol% NaH2PO4·2 H2O. The liquid to
powder ratio (LPR) of each CPC/PLGA/PVP formulation was de-
termined and optimized according to the consistency of the paste. After
LPR optimization for the different CPC formulations, pre-set composites
were fabricated for use in the degradation study. In all PVP containing
formulations, 20 wt.% of PVP particles were added. CPC:PLGA ratio
was kept constant to 60:40. After addition of the liquid phase, the
powder mix was vigorously stirred using a spatula. Hereafter, the ce-
ment paste was molded into a Teflon mold (Ø 9mm×4.5mm) using a
spatula. Afterwards, the composites were left overnight at room tem-
perature. Subsequently, samples were removed from the mold and
freeze-dried.
2.3. Physicochemical characterization of CPCs
2.3.1. Setting time
Initial and final setting times were determined using Gillmore nee-
dles (ASTM C266). With that purpose, the different CPC formulations
were mixed with the setting liquid at the appropriate LPR and molded
into holes (6mm diameter and 12mm of height) of a bronze block
placed in a water bath at 37 °C. Periodically, the light Gillmore needle
(i.e. for initial setting time) or the heavy Gillmore needle (i.e. for final
setting time) were placed onto the surface of the molded CPC. Setting
times were recorded when the needles were not able to mark the CPC
with a complete circular indentation. (n= 3).
2.3.2. Injectability analysis
For injectability analysis, 1 g of each CPC formulation was mixed
with setting liquid at the appropriate LPR. The resulting paste was in-
troduced in a 2.5mL syringe with a nozzle orifice of 2mm in diameter
(Terumo Europe N.V., Leuven, Belgium) and directly extruded. The
extrusion time was kept at 1:30min to avoid interference of extrusion
due to setting time. The injectability (%) was then calculated using Eq.
1., as suggested by Qi et al. (2009) [26].




where mn is the mass of CPC remaining in syringe after injection (g) and
mi is the mass of CPC before injection (g). (n= 3).
2.3.3. Cohesion of the cements
In order to quantify the cohesion, CPC pastes were injected into a
solution of phosphate-buffered saline (PBS; pH 7.4; Gibco®, Thermo
Fischer Scientific, Waltham, MA) heated to 37 °C. Directly upon
Table 1
Material components of the various CPC formulations.
Abbreviation α-TCPa (wt.%) PLGA (wt.%) PVP (wt.%) (type) LPR
CPC 100 0 0 0.5
CPCLh 80 0 20 (L-hMw) 0.3
CPCSh 80 0 20 (S-hMw) 0.3
CPCSl 80 0 20 (S-lMw) 0.3
CPC/PLGA 60 40 0 0.415
CPC/PLGALh 48 32 20 (L-hMw) 0.23
CPC/PLGASh 48 32 20 (S-hMw) 0.23
CPC/PLGASl 48 32 20 (S-lMw) 0.23
a α-TCP, alpha tricalcium phosphate; PLGA, poly(DL-lactic-co-glycolic acid);
PVP, poly(N-vinylpyrrolidone); LPR, liquid-to-powder ratio.
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injection, CPC pastes were photographed and graded on its degree of
particulate cloud formation (PC) and fragmentation (F) as specified in
Table A1 and A2 (Appendix A). Cohesion score was determined fol-
lowing Eq. 2 as described before [27].
= +Cohesion score PC F
2 (2)
To further quantify the quality of cohesion a washout test was
performed as described before [18]. Briefly, the different CPC for-
mulations were mixed with the liquid phase and placed in tissue spe-
cimen bags (pore size 170mm; Thermo Scientific), which were im-
mediately placed in Falcon tubes containing 15mL PBS. Subsequently,
the Falcon tubes were placed on a shaking table for 4 h at 120 rpm in an
incubator at 37 °C. After 4 h, the tissue specimen bags were carefully
removed from the PBS and both the tissue bags and the Falcon tube
containing the PBS were freeze-dried. The weight of both the CPC re-
maining in the bag (WCPC) and the washed-out particles in the tube
(Wwashed) were determined and the wash out % was calculated using







2.3.4. X-ray diffraction analysis
CPCs of each formulation were incubated for 7 days in PBS at 37 °C
to allow full phase transformation. After 7 days, samples were freeze-
dried overnight, ground to powder and analyzed by powder X-ray dif-
fraction (XRD; X'Pert³ Powder, PANalytical, Almelo, The Netherlands)
to determine the crystal phase of the cement composites. XRD spectra
were registered with 2θ from 10° to 60°, a step size of 0.02° and a
counting time of 1 s. XRD spectra of α-TCP and hydroxyapatite (HA)
powders were used as control.
2.4. In vitro degradation studies
To study the degradation of the composites, set samples (n= 4 per
group) were placed in 10ml PBS and incubated at 37 °C for 1, 2, 4 and 6
weeks. Moreover, a short-term degradation study was performed (n= 4
per group), where CPC/PVP and CPC/PLGA/PVP formulations were
incubated in PBS at 37 °C for 1, 2, 4 and 7 days. After each time point,
samples were removed from the PBS and freeze-dried overnight. The
remaining material of the samples was calculated using Eq. 4 below:




where mn is the mass of the sample at t= n (g) and mi is the mass of the
sample at t= 0 (g).
Calcium release and pH were calculated after 1, 2, 4 and 6 weeks of
incubation. The calcium release was evaluated by the o-Cresolphtalein-
Complexone (OCPC) assay, analyzing the samples at a wavelength of
570 nm (BioTek®, Gen5™). This is assay was used as a quantification of
CPC degradation. pH measurements were performed with a pH elec-
trode (Orion, Sigma Aldrich) to quantify PLGA degradation.
2.5. Porosity evaluation
Total and macro-porosity were evaluated by the burn-out method as
described before [28]. The purpose of this method was to burn the
polymeric porogens out of the CPC so a porous structure would be left.
Briefly, set CPCs were subjected to a heating protocol in order to
eliminate the organic components of the cements. The samples were
first heated at a rate of 1.67 °Cmin−1 until reaching 650 °C. Afterwards,
samples were maintained at this temperature for 2 h, and finally tem-
perature was decreased at a rate of 1.67 °Cmin−1 until reaching room
temperature. After burning out the polymeric particles, samples were
weighed, and Eqs. (5) and (6) were used for the derivation of the total



















where mburnt is the average mass macroporous sample (after burning
out the polymers, g), mmicro is the average mass of the microporous CPC
sample (g), V is the volume of the sample (cm3) and ρHA is the density of
the samples (g/cm3). Macroporosity was also observed by scanning
electron microscopy (SEM, Zeiss Sigma 300) after 1 week of incubation
in PBS. Prior to SEM examination, samples were sputter coated with
gold. Images were taken at an accelerating voltage of 3 kV under high
vacuum.
2.6. Statistical analysis
Graphpad Prism 5 (GraphPad Software Inc., San Diego, CA) was
used to analyze the data. Continuous data are expressed as means ±
standard deviations (SD). Statistical differences were only assessed
comparing each sample to their respective control (CPC or CPC/PLGA)
and between samples with different PVP particle size or Mw. Significant
differences between compared groups were determined using analysis
of variance with Tukey’s multiple comparison tests. Results were con-
sidered significant at p values lower than 0.05 (p < 0.05).
3. Results
3.1. Characterization of PVP particles
Figure B1a, b and c (Appendix B) depict a representative image of
PVP L-hMw, S-hMw and S-lMw, respectively. Fig. 1d shows the fre-
quency distribution of the different groups. L-hMw showed a sig-
nificantly larger (p < 0.001) particle size (188 ± 87 μm) than S-hMw
and S-lMw. On the other hand, both groups with small particles (S-hMw
and S-lMw) showed comparable particle sizes (p > 0.05; 50 ± 24 and
46 ± 21 μm).
3.2. Physicochemical characterization of CPCs
3.2.1. Handling properties
Initial and final setting times of the CPC/PVP and CPC/PLGA/PVP
formulations can be observed in Fig. 1a and b. The initial setting time of
control groups (CPC, 1.8 ± 0.1 min and CPC/PLGA, 3.0 ± 0.3min)
was significantly lower compared to PVP containing groups. PVP par-
ticle size nor Mw had a significant impact on initial setting time. Si-
milarly, the final setting time of control groups (CPC, 4.9 ± 0.1 min
and CPC/PLGA, 13.7 ± 1.6min) was significantly lower compared to
PVP containing groups. PVP particle size did not have a significant
impact on final setting time, but CPC/PLGASh had a significantly lower
final setting time than CPC/PLGASl (p < 0.001).
Fig. 1c reveals that paste injectability significantly increased with
the addition of all PVP types compared to CPC to∼85 % (p < 0.01). In
PLGA-containing groups, on the other hand, this effect was not clearly
observed and only the addition of low Mw PVP significantly improved
injectability (p < 0.01).
Figs. 1d and e represent the cohesion of the different CPC pastes.
Addition of PVP significantly improved cohesion compared to CPC
(p < 0.001 when adding high Mw PVP and p < 0.01 when adding
low Mw PVP) and to CPC/PLGA (p < 0.001). PVP particle size did not
have a significant impact on cohesion, but high Mw PVP showed sig-
nificantly lower cohesion values than low Mw PVP (p < 0.001 and
p < 0.05 for PLGA-free and PLGA-containing groups, respectively).
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3.2.2. X-ray diffraction analysis
Fig. 2 shows the powder XRD-patterns of α-TCP and HA powder and
all CPC-porogen formulations. After the samples were incubated in PBS
for 7 days, the α-TCP fully transformed into HA. In all study groups, the
characteristic peaks of α-TCP [29] disappeared and the major reflection
peaks of HA were revealed (at 2Θ=25.9°, 31.7°, 32.2°, 39.8°,46.7°,
49.6° and 53.3°) [30]. Addition of PLGA and PVP did not affect phase
transformation.
3.3. In vitro degradation studies
In vitro degradation of set CPC samples was assessed using mass loss
measurements (Fig. 3). The remaining material (%) of the PLGA-free
composites, as a function of soaking time, is given in Fig. 3a and b. With
no PLGA, pure ceramic (CPC) barely degraded and all the ceramic was
still present after 6 weeks of incubation. Inclusion of PVP particles re-
sulted in significantly less material remaining than CPC at all time
points (p < 0.001). Mass loss started after 1 day of incubation and
gradually continued up to week 4 and the remaining material (%) for
CPCLh, CPCSh and CPCSl was 89.7 ± 1.0, 89.6 ± 0.1 and 87.2 ± 0.7
%, respectively. PVP particle size had no significant effect on de-
gradation (p > 0.05). Low Mw PVP, on the other hand, significantly
increased mass loss after 4 and 7 days of incubation (p < 0.001).
The remaining material (%) of the PLGA-containing composites, as a
function of soaking time, is shown in Fig. 3c and d. CPCs containing
PLGA revealed considerable mass loss during the 6 weeks of incubation
and the minimum amount of remaining material was 34.6 ± 2.3 % for
CPC/PLGASl. CPC/PLGA-only samples started to degrade after 1 week
Fig. 1. Handling properties of CPC composites: (a) initial and (b) final (min) setting times; (c) injectability % and (d) cohesion score of the different cement
formulations (n=3); *p < 0.05, **p < 0.01, and ***p < 0.001; ns: not significant differences; error bars represent standard deviation (SD). (e) Representative
digital images of CPC composites injected into PBS heated to 37 °C used to calculate the cohesion score.
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of incubation. Inclusion of PVP particles resulted in significantly less
remaining material compared with CPC/PLGA specimens, especially at
early time points. Incorporation of small PVP particles resulted in
significantly less remaining material after 2 weeks of incubation com-
pared to incorporation of large PVP particles (p < 0.001). Incorpora-
tion of hMw PVP, on the other hand, had no significant effect after 2
weeks of incubation (p > 0.05), but incorporation of lMw PVP en-
hanced mass loss after 4 and 6 weeks of incubation.
PLGA degradation results in formation of acidic by-products (i.e.
lactic and glycolic acid), which were quantified by means of pH change
(Fig. 3e). CPC and CPC/PVP composites revealed a marginal pH de-
crease. In contrast, CPC/PLGA and CPC/PLGA/PVP composites de-
creased the pH of the incubation medium for all experimental groups.
CPC/PLGA showed a substantial pH decrease after 2 weeks compared to
PVP-containing groups (p < 0.001). PVP particle size and Mw had a
significant impact on pH decrease at an early stage (i.e. weeks 1 and 2
of incubation; p < 0.001).
Also, CPC degradation was quantified by means of calcium (Ca2+)
release (Fig. 3f). For CPC and CPC/PVP composites, Ca2+ release was
limited. After 1 week of incubation, all samples released ∼70 μg of
Ca2+. Between week 1 and week 6 no further significant release was
observed for CPC, CPCLh and CPCSh (p > 0.05), only CPCSl showed a
slight increase in release up to week 4 (p < 0.001). Ca2+ release from
Fig. 2. XRD patterns of α-TCP and HA powders (controls) and the different
CPC-porogen formulations after 7 days of incubation, showing transition of α-
TCP to HA upon immersion in aqueous solution for all formulations.
Fig. 3. Degradation of CPC composites. (a) Mass loss of PLGA-free groups represented by the remaining material as a function of degradation time and (b) mag-
nification of the mass loss in week 1. (c) Mass loss of PLGA-containing groups represented by the remaining material as a function of degradation time and (d)
magnification of the mass loss in week 1. (e) pH and (f) calcium release of each cement formulation to the surrounding PBS. Error bars represent SD.
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CPC/PLGA and CPC/PLGA/PVP samples was significantly higher than
CPC and CPC/PVP at all time points (p < 0.001). Similar to pH mea-
surements, PVP particle size and Mw had a stronger effect at early time
points (i.e. weeks 1 and 2, p < 0.001) than at later time points.
3.4. Porosity evaluation
SEM images (Figure B1) were taken after 1 week of incubation. It
was observed that PVP had already dissolved while PLGA was still
present. Total porosity and macroporosity of the different composites
were studied and are shown in Fig. 4. Total porosity of CPC was
60.6 ± 0.3 %. Inclusion of PVP particles significantly increased the
total porosity (p < 0.001) to 67.8 ± 0.6, 68.2 ± 0.5 and 65.6 ± 0.5
% for CPCLh, CPCSh and CPCSl, respectively. High-Mw PVP significantly
increased total porosity (p < 0.05). On the other hand, macroporosity
was also significantly increased (p < 0.001) for CPC/PVP composites
in comparison to CPC, but PVP particle size or Mw did not affect
macroporosity (p > 0.05). CPC/PLGA composites showed a higher
total porosity than CPC composites. CPC/PLGA, CPC/PLGALh, CPC/
PLGASh and CPC/PLGASl had a total porosity of 80.7 ± 1.8,
75.5 ± 0.6, 83.2 ± 0.2 and 81.4 ± 0.7 %, respectively. Similarly,
macroporosity values followed a similar trend to total porosity values.
4. Discussion
The aim of our study was to investigate the potential use of the
water-soluble porogen PVP to rapidly achieve macroporosity formation
within CPC and CPC/PLGA composites. Additionally, the effect of PVP
porogen particle size and molecular weight (Mw) was evaluated. Two
different particles sizes (large and small, ∼50 and ∼200 μm, respec-
tively) and two different Mw (high and low, 360 and 10 kDa, respec-
tively) were selected and their effect of on the physicochemical,
handling, and in vitro degradation characteristics of CPC and CPC/PLGA
composites was assessed. Our results revealed that the initial and final
setting time of CPC and CPC/PLGA composites were increased upon the
incorporation of PVP, but the phase transformation to hydroxyapatite
was not hindered. PVP incorporation improved CPC injectability and
cohesion. Furthermore, the in vitro degradation studies showed that the
incorporation of PVP porogens increased mass loss at an early stage
compared to CPC and CPC/PLGA.
The physicochemical properties and handling properties (i.e. setting
times, injectability and cohesion) of the different composites were de-
termined. Initial setting time has been described as the clinical window
during which it is possible to inject the CPC and mold it to fill the
dimensions of the defect, while final setting time indicates the time
needed before the wound can be closed. Ideally, initial setting time
should be between 3 and 8min and final setting time should not exceed
15min [31]. Here, initial setting times complied with these specifica-
tions, but final setting times exceeded this requirement, especially when
PLGA and PVP porogens were combined within one CPC formulation. It
has been described that an increase in the salt concentration of the li-
quid phase could lead to shorter setting times [31,32]. In order to de-
crease final setting time a preliminary study was performed with S-lMw
PVP by modifying the liquid phase concentration from 4wt/vol % to
20wt/vol % aqueous solution of NaH2PO4·2 H2O. As no clear benefits
were observed (data not shown), 4 wt/vol % was chosen for the rest of
the study for standardization purposes. Others have described that the
addition of water-soluble porogens (i.e. sucrose and glucose) sig-
nificantly increases final setting time, which limits their clinical ap-
plicability [18,33,34]. On the other hand, while those studies showed
final setting times close to 50min (i.e. for glucose) [33] and of∼35min
and ∼80min (i.e. for sucrose without and with PLGA, respectively)
[18], the currently observed increase upon addition of PVP porogens
was evidently lower. The increase in setting time is likely related to the
higher hydrophilicity of the water-soluble porogens compared to the
CaP ceramic, which extracts water from the cement and results in in-
creased setting time [34,35]. In addition, the use of low Mw PVP caused
higher final setting times than high Mw PVP. This is possibly due to the
faster dissolution rate of low Mw PVP, which consumes more water
[36]. This hypothesis is supported by the work of Majekodunmi and
Deb (2007), who incorporated another water-soluble polymer and re-
ported a similar influence of molecular weight [37]. This increase in
final setting time upon the addition of PLGA and PVP porogens did not
hamper the phase transformation from α-TCP to HA.
Cement injectability generally was improved by the addition of PVP.
All CPC/PVP composites as well as CPC/PLGASl were found to be in-
jectable. However, in combination with PLGA, formulations containing
high Mw PVP showed an injectability of< 70 %. This is due to the fact
that higher Mw PVP increases the viscosity of the liquid component
[36], and when incorporated into CPC/PLGA results in pastes with a
very high viscosity hampering extrusion from the syringe. It has been
previously described that CPC pastes suffer from filter pressing, which
means that when injected, the liquid phase of the CPC flows at a faster
rate than the powder phase, leading to phase separation [27,38–40].
Here, CPC and CPC/PLGA formulations indeed suffered from this phase
separation process, while PVP porogen incorporation diminished this
effect. Evidently, the PVP acts as a lubricant and facilitates injectability.
As observed previously, cement cohesion was improved upon ad-
dition of PVP [24], with high Mw PVP showing excellent cohesion
properties. CPC cohesion is of high importance as CPC leakage can
induce an inflammatory reaction, blood clotting or pulmonary embo-
lism, which can endanger the life of the patient [41–43]. While plain
CPC paste showed bad cohesion due to a high fragmentation of the
paste, CPC/PLGA showed fewer fragmentation. On the other hand, a
large particulate cloud was formed, which has higher risk of leakage.
Therefore, the enhancement of the cohesion in the PLGA-containing
composites is of paramount importance. It has been described that paste
viscosity can increase the cohesion of the CPC [44,45]. In view of this,
PVPs with higher Mw generate solutions with higher viscosities that
increase the cohesion of the paste. Others have incorporated carbox-
ymethyl cellulose (CMC) into CPCs to improve their cohesive and lu-
bricative properties [17,27,46–48]. Our study indicated that the in-
clusion of high Mw PVP performed as well as CMC. An additional
advantage is that PVP Mw is not affected by gamma radiation ster-
ilization [36]. This in contrast to CMC that is damaged by gamma ra-
diation due to the breakage of the glycosidic bonds, which results in a
reduced paste cohesion for CMC-containing CPC [27,49]. Consequently,
PVP Mw might be an alternative to CMC as a cohesion promotor.
Several studies have investigated the in vitro degradation of CPC/
PLGA composites and compared it to CPC [18,28,33,50–52]. In agree-
ment with these studies, our data confirmed that the addition of PLGA
enhances CPC degradation, which can be concluded from the higher
mass loss, the lower pH and the increased calcium released into the
incubation medium from PLGA-containing composites compared to the
PLGA-free ones. Further, the data demonstrated that the in vitro de-
gradation of CPC/PLGA composites did not occur during the first week
Fig. 4. Total porosity and macroporosity (%) of CPC composited measured by
the burn-out method. Error bars represent SD.
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of incubation. In contrast, the addition of PVP porogens of any size and
Mw resulted in a higher mass loss during the first week of incubation
than CPC and CPC/PLGA composites. This increase in mass loss as such
can be attributed to the PVP dissolution and coincides with the for-
mation of macroporosity at an early stage. This initial mass loss oc-
curred gradually and can prevent partial dissolution before setting,
which would avoid CPC matrix densification.
The effect of pore size of bone substitutes on bone regeneration has
already been extensively studied. However, limited agreement has been
reached. While some suggest that the optimal pore size for bone in-
growth ranges from 80−400 μm [13,53,54], others have observed that
pore sizes as small as 25 or 50 μm are sufficient for bone ingrowth
[55–57]. In the current study, porogen sizes of∼50 and∼200 μm were
selected. We observed that the mass loss using small PVP porogens was
faster than using large PVP porogens, but the overall mass loss after 6
weeks was similar using both porogen sizes. This might be related to the
fact that smaller particles have larger surface area to volume ratio,
which speeds up the dissolution process. In contrast, the dissolution of
the larger PVP particles occurs in a more gradual manner, which may
be beneficial to avoid partial dissolution during setting. Feng et al. [58]
studied the effect of pore size on in vitro degradation of CPC and ob-
served that larger macropores enhanced CPC degradation due to an
increase of the surface area. Further, Smith et al. [34] observed that the
interconnectivity of the pores was enhanced with the addition of larger
porogens. Therefore, the incorporation of large PVP porogens into CPC
seems to be preferable. However, it has to be taken into account that
this incorporation might be detrimental to the mechanical properties of
the CPCs, as previously described [19,59].
It is known that the degradation rate of biodegradable polymers
depends on the molecular weight, i.e. how lower the molecular weight,
how faster the degradation [60]. In line with this, the effect of porogen
Mw was investigated, which revealed that the mass loss in CPCs was
enhanced at an early stage by the addition of low Mw PVP particles
compared to high Mw particles. This early stage mass loss enhancement
was also translated into an overall higher mass loss when combined
with PLGA. This corroborates with previous studies, which showed that
the dissolution rate of PVP was inversely proportional to its Mw
[61–63]. It was concluded that this was due to the higher viscosity and
hydrophobicity of high Mw PVP, and hence decreased wettability. To
the best of our knowledge, PVP has never been incorporated into CPCs
to accelerate degradation. Nevertheless, the effect of Mw of other
polymeric porogens on CPC degradation has been studied. For instance,
it was observed that PLGA porogens with low Mw enhanced faster CPC
degradation in vitro [15]. Finally, it has been reported that low Mw
PLGA porogens induced a superior bone formation compared with high
Mw PLGA porogens, which was related to the faster degradation rate of
low Mw PLGA [64].
5. Conclusion
The current study evaluated the inclusion of water-soluble PVP
polymer into CPC and CPC/PLGA composites. Inclusion of PVP particles
improved the injectability and cohesion of the CPC paste by increasing
paste viscosity, but it also increased setting time. CPC and CPC/PLGA
composites showed an increased early stage mass loss when PVP par-
ticles were incorporated. Low Mw weight PVP showed a faster dis-
solution rate than high Mw PVP. Particle size, on the other hand, had no
large effect, but smaller-sized particles dissolved faster than larger ones.
Overall, PVP Mw had a much stronger effect on handling properties and
in vitro degradation than particle size. In conclusion, a correct fine-
tuning of PVP particle size and, most importantly, Mw is of high im-
portance to achieve CPC with excellent handling properties and de-
gradation behavior.
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